{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:36:32Z","timestamp":1793306192746,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174040"],"award-info":[{"award-number":["82174040"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.metabol.2024.156043","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:23:25Z","timestamp":1727677405000},"page":"156043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"161","author":[{"given":"Ru-Tao","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin-Mei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Han","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2024.156043_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155999","article-title":"Global burden of metabolic diseases, 1990\u20132021","volume":"160","author":"Zhang","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156043_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155664","article-title":"From non-alcoholic fatty liver disease (nafld) to steatotic liver disease (sld): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need","volume":"147","author":"Kokkorakis","year":"2023","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.metabol.2024.156043_bb0015","first-page":"691","article-title":"Masld: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2024.156043_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155931","article-title":"Dcrm 2.0: multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","volume":"159","author":"Handelsman","year":"2024","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.metabol.2024.156043_bb0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41581-021-00519-y","article-title":"Association of metabolic dysfunction-associated fatty liver disease with kidney disease","volume":"18","author":"Wang","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156043_bb0030","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","article-title":"Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease","volume":"21","author":"Feng","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156043_bb0035","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/pharmrev.123.001087","article-title":"Steatotic liver disease: pathophysiology and emerging pharmacotherapies","volume":"76","author":"Kokkorakis","year":"2024","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.metabol.2024.156043_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.metabol.2024.156043_bb0045","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The firstmash drug therapy on the horizon: current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.metabol.2024.156043_bb0050","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metab"},{"issue":"7","key":"10.1016\/j.metabol.2024.156043_bb0055","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/apt.17889","article-title":"Meta-analysis: efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non-alcoholic steatohepatitis and non-alcoholic steatohepatitis-related fibrosis","volume":"59","author":"Lin","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.metabol.2024.156043_bb0060","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/gutjnl-2023-331115","article-title":"Fgf-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials","volume":"73","author":"Mantovani","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2024.156043_bb0065","doi-asserted-by":"crossref","first-page":"155332","DOI":"10.1016\/j.metabol.2022.155332","article-title":"Pharmacotherapy of type 2 diabetes: an update and future directions","volume":"137","author":"Demarsilis","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156043_bb0070","doi-asserted-by":"crossref","first-page":"155710","DOI":"10.1016\/j.metabol.2023.155710","article-title":"Safety and efficacy of the new, oral, small-molecule, glp-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials","volume":"149","author":"Karakasis","year":"2023","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.metabol.2024.156043_bb0075","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"22","author":"Abushamat","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"15","key":"10.1016\/j.metabol.2024.156043_bb0080","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","article-title":"Transforming obesity: the advancement of multi-receptor drugs","volume":"187","author":"Kusminski","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2024.156043_bb0085","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000860","article-title":"Mash clinical trials and drugs pipeline: an impending tsunami","author":"Noureddin","year":"2024","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.metabol.2024.156043_bb0090","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/apt.16808","article-title":"Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a bayesian network meta-analysis","volume":"55","author":"Ng","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.metabol.2024.156043_bb0095","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of nash","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.156043_bb0100","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001028","article-title":"Comparative efficacy of pharmacologic therapies for mash in reducing liver fat content: systematic review and network meta-analysis","author":"Koh","year":"2024","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.metabol.2024.156043_bb0105","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in nash with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.metabol.2024.156043_bb0110","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"10213","key":"10.1016\/j.metabol.2024.156043_bb0115","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (mgl-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156043_bb0120","series-title":"Gannex announces positive interim results from 52-week phase ii clinical trial of once-daily asc41 tablet in patients with biopsy-confirmed non-alcoholic steatohepatitis","year":"2024"},{"key":"10.1016\/j.metabol.2024.156043_bb0125","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/S0168-8278(24)00612-3","article-title":"Lbp-045 efficacy and safety of hsk31679, a thyroid hormone receptor \u03b2 agonist, for the treatment of asian non-alcoholic fatty liver disease: a multicenter randomized, double-blind, placebo-controlled, phase 2a trial","volume":"80","author":"Xue","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156043_bb0130","series-title":"Terns achieves primary endpoint and all secondary endpoints in phase 2a duet trial of thr-\u00df agonist tern-501 in nash | terns pharmaceuticals, inc","year":"2023"},{"key":"10.1016\/j.metabol.2024.156043_bb0135","series-title":"Viking therapeutics announces positive 52-week histologic data from phase 2b voyage study of vk2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (nash)","year":"2024"},{"issue":"6","key":"10.1016\/j.metabol.2024.156043_bb0140","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.metabol.2024.156043_bb0145","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.metabol.2024.156043_bb0150","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"10019","key":"10.1016\/j.metabol.2024.156043_bb0155","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (lean): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156043_bb0160","series-title":"Akero therapeutics reports statistically significant histological improvements at week 96 in phase 2b harmony study","year":"2024"},{"issue":"1","key":"10.1016\/j.metabol.2024.156043_bb0165","article-title":"A randomized, double-blind, placebo-controlled phase iia trial of efruxifermin for patients with compensated nash cirrhosis","volume":"5","author":"Harrison","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.metabol.2024.156043_bb0170","series-title":"Akero therapeutics reports encouraging 36-week analysis of 96-week phase 2b symmetry study, with a trend on fibrosis improvement and statistically significant results for nash resolution, markers of liver injury and fibrosis, insulin sensitization and lip","year":"2023"},{"issue":"7","key":"10.1016\/j.metabol.2024.156043_bb0175","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.metabol.2024.156043_bb0180","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the fgf21 analogue pegozafermin in nash","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.metabol.2024.156043_bb0185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156043_bb0190","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (falcon 1): a randomized phase 2b study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156043_bb0195","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (falcon 2): a randomized phase 2b study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10165","key":"10.1016\/j.metabol.2024.156043_bb0200","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (bms-986036), a pegylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156043_bb0205","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-8278(23)00604-9","article-title":"Twelve-week treatment with bos-580, a novel, long-acting fc-fgf-21 fusion protein, leads to a reduction in liver steatosis, liver injury, and fibrosis in patients with phenotypic nash: a randomized, blinded, placebo-controlled phase 2a trial","volume":"78","author":"Loomba","year":"2023","journal-title":"J Hepatol"},{"issue":"17","key":"10.1016\/j.metabol.2024.156043_bb0210","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-ppar agonist lanifibranor in nash","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156043_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a glp-1\/glucagon dual receptor agonist, on masld: a randomized, double-blind, placebo-controlled study","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.metabol.2024.156043_bb0220","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","article-title":"Safety and efficacy of novel incretin co-agonist cotadutide in biopsy-proven noncirrhotic mash with fibrosis","volume":"22","author":"Shankar","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156043_bb0225","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in mash and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.metabol.2024.156043_bb0230","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.metabol.2024.156043_bb0235","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2024.156043_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155936","article-title":"Metabolic dysfunction-associated steatotic liver disease: recent turning points for its diagnosis and management","volume":"157","author":"Polyzos","year":"2024","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2024.156043_bb0245","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in nash drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.metabol.2024.156043_bb0250","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S2468-1253(23)00066-3","article-title":"Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"8","author":"Tincopa","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156043_bb0255","article-title":"Easl\u2013easd\u2013easo clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (masld): executive summary","author":"European AFTS, European AFTS, European AFTS","year":"2024","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.metabol.2024.156043_bb0260","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.1016\/j.metabol.2024.156043_bb0265","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.metabol.2024.156043_bb0270","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.metabol.2024.156043_bb0275","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.metabol.2024.156043_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2024.156043_bb0285","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"Fgf21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156043_bb0290","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s44355-024-00004-w","article-title":"Resmetirom and glp-1 agonists for mash: complementary rather than exclusive","volume":"1","author":"Zhou","year":"2024","journal-title":"npj Gut Liver"},{"key":"10.1016\/j.metabol.2024.156043_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.02.022","article-title":"Safety and efficacy of efruxifermin in combination with a glp-1 receptor agonist in patients with nash\/mash and type 2 diabetes in a randomized phase 2 study","author":"Harrison","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"23","key":"10.1016\/j.metabol.2024.156043_bb0300","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMc2311873","article-title":"Randomized trial of pegozafermin in nash","volume":"389","author":"Patoulias","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524002713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524002713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T22:14:13Z","timestamp":1731708853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524002713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":60,"alternative-id":["S0026049524002713"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156043","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156043"}}